Ultragenyx Pharmaceutical Inc
For the period ended Mar 31, 2025. Filed May 7, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 7, 2025
RARE$16.41+6.4%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
| Incorporated by Reference | |||||
|---|---|---|---|---|---|
| Exhibit Number | Exhibit Description | Form | Date | Number | Furnished or Filed Herewith |
| 3.1 | Amended and Restated Certificate of Incorporation | 8-K | 2/5/2014 | 3.1 | |
| 3.2 | Second Amended and Restated Bylaws | 8-K | 12/23/2023 | 3.1 | |
| 4.1 | Form of Common Stock Certificate | S-1 | 11/8/2013 | 4.2 | |
| 4.2 | Form of Indenture | S-3ASR | 2/21/2024 | 4.2 | |
| 4.3 | Form of Pre-Funded Warrant | 8-K | 10/23/2023 | 4.1 | |
| 4.4 | Form of Pre-Funded Warrant | 8-K | 6/17/2024 | 4.1 | |
| 10.1# | Form of Performance Stock Unit Agreement (2025) | X | |||
| 31.1 | Certification of Principal Executive Officer Required Under Rule 13a-14(a) or Rule 15d-14(a) of the Exchange Act | X | |||
| 31.2 | Certification of Principal Financial Officer Required Under Rule 13a-14(a) or Rule 15d-14(a) of the Exchange Act | X | |||
| 32.1* | Certification of Principal Executive Officer and Principal Financial Officer Required Under Rule 13a-14(b) or Rule 15d-14(b) of the Exchange Act and 18 U.S.C. 1350 | X | |||
| 101.INS | XBRL Instance Document, formatted in Inline XBRL | X | |||
| 101.SCH | Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents | X | |||
| 104 | Cover Page Interactive Data File, formatted in Inline XBRL (included in Exhibit 101). | ||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.